The Latin America, Middle East and Africa Real World Evidence Solutions Market would witness market growth of 10.7% CAGR during the forecast period (2022-2028).
RWE is being utilized by pharma in more novel ways. RWE is used by some for clinical trial planning and recruiting. In contrast, others use it for post-market safety and unfavorable event monitoring or financial analyses relating to payer reimbursement. Some companies are incorporating ways to continuous learning into their lifecycle of product development.
Additionally, digital health innovation has considerably improved wearable technology's capabilities, which has led to a rise in the usage of recent technological advancements in clinical studies. More than 1,000 completed or continuing clinical research involving wearables were listed in the ClinicalTrials.gov database, mainly in oncology, neuroscience, and respiratory and metabolic illnesses. These developments are fostering the market for real-world evidence solutions.
The regional healthcare industry's future is shaped by several elements, which is why the trend is altering. Rising healthcare costs, shifting population & disease demographics, increased healthcare quality emphasis, medical data digitization, rising demand for regional clinical & economic data, and a general influence of worldwide trends in the medical industry are some of the other factors. However, for the region to fully benefit from RWE in treatment decisions, it must overcome some obstacles, such as accepting the worth that RWE puts to healthcare decisions, and fostering trust among stakeholders. Additionally, establishment of the validity & reliability of the databases utilized to generate RWE, investment in the generation of local data, and improving technical capabilities would benefit the market. These factors would further proliferate the undertaking of high-quality RWE research while protecting patient confidentiality. These rising healthcare sector would drive the demand of Real World Evidence Solutions Market in LAMEA.
The Brazil market dominated the LAMEA Real World Evidence Solutions Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $933 million by 2028.The Argentina market is exhibiting a CAGR of 11.3% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 10.4% during (2022 - 2028).
Based on Component, the market is segmented into Services and Data Set. Based on Therapeutic Area, the market is segmented into Oncology, Cardiology, Neurology, Diabetes, Respiratory and Others. Based on End-user, the market is segmented into Healthcare Companies, Healthcare Payers, Healthcare Providers and Others. Based on Application, the market is segmented into Drug Development & Approvals, Medical Device Development & Approvals, Reimbursement/Coverage & Regulatory Decision Making and Post Market Safety & Adverse Events Monitoring. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include IBM Corporation, Oracle Corporation, Medpace Holdings, Inc., IQVIA Holdings, Inc., ICON plc, PerkinElmer, Inc., Parexel International Corporation (Phoenix Parentco, Inc.), PPD, Inc. (Thermo Fisher Scientific, Inc.), UnitedHealth Group, Inc. (Optum, Inc.), and Syneos Health, Inc.
RWE is being utilized by pharma in more novel ways. RWE is used by some for clinical trial planning and recruiting. In contrast, others use it for post-market safety and unfavorable event monitoring or financial analyses relating to payer reimbursement. Some companies are incorporating ways to continuous learning into their lifecycle of product development.
Additionally, digital health innovation has considerably improved wearable technology's capabilities, which has led to a rise in the usage of recent technological advancements in clinical studies. More than 1,000 completed or continuing clinical research involving wearables were listed in the ClinicalTrials.gov database, mainly in oncology, neuroscience, and respiratory and metabolic illnesses. These developments are fostering the market for real-world evidence solutions.
The regional healthcare industry's future is shaped by several elements, which is why the trend is altering. Rising healthcare costs, shifting population & disease demographics, increased healthcare quality emphasis, medical data digitization, rising demand for regional clinical & economic data, and a general influence of worldwide trends in the medical industry are some of the other factors. However, for the region to fully benefit from RWE in treatment decisions, it must overcome some obstacles, such as accepting the worth that RWE puts to healthcare decisions, and fostering trust among stakeholders. Additionally, establishment of the validity & reliability of the databases utilized to generate RWE, investment in the generation of local data, and improving technical capabilities would benefit the market. These factors would further proliferate the undertaking of high-quality RWE research while protecting patient confidentiality. These rising healthcare sector would drive the demand of Real World Evidence Solutions Market in LAMEA.
The Brazil market dominated the LAMEA Real World Evidence Solutions Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $933 million by 2028.The Argentina market is exhibiting a CAGR of 11.3% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 10.4% during (2022 - 2028).
Based on Component, the market is segmented into Services and Data Set. Based on Therapeutic Area, the market is segmented into Oncology, Cardiology, Neurology, Diabetes, Respiratory and Others. Based on End-user, the market is segmented into Healthcare Companies, Healthcare Payers, Healthcare Providers and Others. Based on Application, the market is segmented into Drug Development & Approvals, Medical Device Development & Approvals, Reimbursement/Coverage & Regulatory Decision Making and Post Market Safety & Adverse Events Monitoring. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include IBM Corporation, Oracle Corporation, Medpace Holdings, Inc., IQVIA Holdings, Inc., ICON plc, PerkinElmer, Inc., Parexel International Corporation (Phoenix Parentco, Inc.), PPD, Inc. (Thermo Fisher Scientific, Inc.), UnitedHealth Group, Inc. (Optum, Inc.), and Syneos Health, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Component
- Services
- Data Set
By Therapeutic Area
- Oncology
- Cardiology
- Neurology
- Diabetes
- Respiratory
- Others
By End-user
- Healthcare Companies
- Healthcare Payers
- Healthcare Providers
- Others
By Application
- Drug Development & Approvals
- Medical Device Development & Approvals
- Reimbursement/Coverage & Regulatory Decision Making
- Post Market Safety & Adverse Events Monitoring
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- IBM Corporation
- Oracle Corporation
- Medpace Holdings, Inc
- IQVIA Holdings, Inc
- ICON plc
- PerkinElmer, Inc
- Parexel International Corporation (Phoenix Parentco, Inc.)
- PPD, Inc. (Thermo Fisher Scientific, Inc.)
- UnitedHealth Group, Inc. (Optum, Inc.)
- Syneos Health, Inc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Real World Evidence Solutions Market, by Component
1.4.2 LAMEA Real World Evidence Solutions Market, by Therapeutic Area
1.4.3 LAMEA Real World Evidence Solutions Market, by End-user
1.4.4 LAMEA Real World Evidence Solutions Market, by Application
1.4.5 LAMEA Real World Evidence Solutions Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Scenario and Composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Real World Evidence Solutions Market
Chapter 4. LAMEA Real World Evidence Solutions Market by Component
4.1 LAMEA Services Market by Country
4.2 LAMEA Data Set Market by Country
Chapter 5. LAMEA Real World Evidence Solutions Market by Therapeutic Area
5.1 LAMEA Oncology Market by Country
5.2 LAMEA Cardiology Market by Country
5.3 LAMEA Neurology Market by Country
5.4 LAMEA Diabetes Market by Country
5.5 LAMEA Respiratory Market by Country
5.6 LAMEA Others Market by Country
Chapter 6. LAMEA Real World Evidence Solutions Market by End-user
6.1 LAMEA Healthcare Companies Market by Country
6.2 LAMEA Healthcare Payers Market by Country
6.3 LAMEA Healthcare Providers Market by Country
6.4 LAMEA Others Market by Country
Chapter 7. LAMEA Real World Evidence Solutions Market by Application
7.1 LAMEA Drug Development & Approvals Market by Country
7.2 LAMEA Medical Device Development & Approvals Market by Country
7.3 LAMEA Reimbursement/Coverage & Regulatory Decision Making Market by Country
7.4 LAMEA Post Market Safety & Adverse Events Monitoring Market by Country
Chapter 8. LAMEA Real World Evidence Solutions Market by Country
8.1 Brazil Real World Evidence Solutions Market
8.1.1 Brazil Real World Evidence Solutions Market by Component
8.1.2 Brazil Real World Evidence Solutions Market by Therapeutic Area
8.1.3 Brazil Real World Evidence Solutions Market by End-user
8.1.4 Brazil Real World Evidence Solutions Market by Application
8.2 Argentina Real World Evidence Solutions Market
8.2.1 Argentina Real World Evidence Solutions Market by Component
8.2.2 Argentina Real World Evidence Solutions Market by Therapeutic Area
8.2.3 Argentina Real World Evidence Solutions Market by End-user
8.2.4 Argentina Real World Evidence Solutions Market by Application
8.3 UAE Real World Evidence Solutions Market
8.3.1 UAE Real World Evidence Solutions Market by Component
8.3.2 UAE Real World Evidence Solutions Market by Therapeutic Area
8.3.3 UAE Real World Evidence Solutions Market by End-user
8.3.4 UAE Real World Evidence Solutions Market by Application
8.4 Saudi Arabia Real World Evidence Solutions Market
8.4.1 Saudi Arabia Real World Evidence Solutions Market by Component
8.4.2 Saudi Arabia Real World Evidence Solutions Market by Therapeutic Area
8.4.3 Saudi Arabia Real World Evidence Solutions Market by End-user
8.4.4 Saudi Arabia Real World Evidence Solutions Market by Application
8.5 South Africa Real World Evidence Solutions Market
8.5.1 South Africa Real World Evidence Solutions Market by Component
8.5.2 South Africa Real World Evidence Solutions Market by Therapeutic Area
8.5.3 South Africa Real World Evidence Solutions Market by End-user
8.5.4 South Africa Real World Evidence Solutions Market by Application
8.6 Nigeria Real World Evidence Solutions Market
8.6.1 Nigeria Real World Evidence Solutions Market by Component
8.6.2 Nigeria Real World Evidence Solutions Market by Therapeutic Area
8.6.3 Nigeria Real World Evidence Solutions Market by End-user
8.6.4 Nigeria Real World Evidence Solutions Market by Application
8.7 Rest of LAMEA Real World Evidence Solutions Market
8.7.1 Rest of LAMEA Real World Evidence Solutions Market by Component
8.7.2 Rest of LAMEA Real World Evidence Solutions Market by Therapeutic Area
8.7.3 Rest of LAMEA Real World Evidence Solutions Market by End-user
8.7.4 Rest of LAMEA Real World Evidence Solutions Market by Application
Chapter 9. Company Profiles
9.1 IBM Corporation
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional & Segmental Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Acquisition and Mergers:
9.1.6 SWOT Analysis
9.2 Oracle Corporation
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 PPD, Inc. (Thermo Fisher Scientific, Inc.)
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 SWOT Analysis
9.4 UnitedHealth Group, Inc. (Optum, Inc.)
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental Analysis
9.5 Syneos Health, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Recent strategies and developments:
9.5.4.1 Acquisition and Mergers:
9.6 IQVIA Holdings, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Recent strategies and developments:
9.6.4.1 Partnerships, Collaborations, and Agreements:
9.6.4.2 Acquisition and Mergers:
9.7 Medpace Holdings, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.8 ICON plc
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Recent strategies and developments:
9.8.4.1 Acquisition and Mergers:
9.9 PerkinElmer, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Product Launches and Product Expansions:
9.10. Parexel International Corporation (Phoenix Parentco, Inc.)
9.10.1 Company Overview
9.10.2 Recent strategies and developments:
9.10.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- IBM Corporation
- Oracle Corporation
- Medpace Holdings, Inc.
- IQVIA Holdings, Inc.
- ICON plc
- PerkinElmer, Inc.
- Parexel International Corporation (Phoenix Parentco, Inc.)
- PPD, Inc. (Thermo Fisher Scientific, Inc.)
- UnitedHealth Group, Inc. (Optum, Inc.)
- Syneos Health, Inc.
Methodology
LOADING...
